Journal Scans
Factor V Leiden Mutation and Thromboembolism Risk in Women Receiving Adjuvant Tamoxifen for Breast Cancer
FVL Mutation Increases Risk of Tamoxifen-Induced Thromboembolism
JE Garber, S Halabi, SM Tolaney, E Kaplan, L Archer, JN Atkins, S Edge, CL Shapiro, L Dressler, EM Paskett, G Kimmick, J Orcutt, A Scalzo, E Winer, E Levine, N Shahab, N Berliner, for the Cancer and Leukemia Group B
Yes
20100607
2010 Jul 7
J Natl Cancer Inst
Factor V Leiden Mutation and Thromboembolism Risk in Women Receiving Adjuvant Tamoxifen for Breast Cancer
J Natl Cancer Inst. 2010 Jul 7;102(13):942-949, JE Garber, S Halabi, SM Tolaney, E Kaplan, L Archer, JN Atkins, S Edge, CL Shapiro, L Dressler, EM Paskett, G Kimmick, J Orcutt, A Scalzo, E Winer, E Levine, N Shahab, N Berliner, for the Cancer and Leukemia Group B
TAKE-HOME MESSAGE
EXPERT COMMENTARY
Abstract
SUMMARY
OncologySTAT Editorial Team
Thromboembolic events (TEs) are a well-documented, serious complication associated with use of tamoxifen. Women with breast cancer may be at increased risk for TEs for various reasons; the underlying effect of breast cancer itself in the development of tamoxifen-associated thromboembolism is unquantified. Hereditary thrombotic predisposition is associated with the dominant Leiden variant of the Factor V (FVL) gene. With FVL, a single nucleotide polymorphism occurs at position 1691 of the Factor V...
